Department of Nuclear Medicine and PET-CT Center (Liang M,Zheng R,Wu N, Zhang WJ,Liang Y,Liu Y,Li XM,Fang Y,Chen C),Department of Radiation Oncology (Zhou ZM,Xiao ZF,Feng QF,Wang LH,Li YX),Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,ChinaZheng Rong,Email:zrong99@163.com
Abstract：Objective To investigate the metabolic parameters of primary lesions of non-small cell lung cancer (NSCLC) obtained by 18F-FDG PET/CT and their prognostic values in patients with NSCLC who underwent radiotherapy. Methods The clinical data of 170 NSCLC patients who underwent PET/CT scan before the first course of radiotherapy in Cancer Hospital, Chinese Academy of Medical Sciences, from January 2007 to December 2013 were analyzed retrospectively. The prognostic values of clinical factors, maximum standard uptake value (SUVmax) standard uptake value (SUVmean), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) were analyzed. The Kaplan-Meier method was applied for univariate survival analysis, the log-rank test was applied to compare the survival rate between groups, and the Cox proportional hazards regression was applied for multivariate survival analysis;P<0.05 was consideredstatistically significant. The number of patients who received the follow-up visit at 5 years were 48. Results The 5-year overall survival was 24.7%. The univariate analysis showed that age, N stage, clinical TNM stage, tumor size, SUVmax, MTV, and TLG were the prognostic factors in NSCLC patients who underwent radiotherapy (P=0.001-0.040). The Cox proportional hazards regression analysis of the above parameters showed that age and MTV of the primary lesion were the independent prognostic factors for overall survival (P=0.016,0.005). Conclusions Age, N stage, clinical TNM stage, tumor size, SUVmax, MTV, and TLG are the prognostic factors in NSCLC patients undergoing radiotherapy, while age and MTV of the primary lesion are the independent prognostic factors.
. Prognostic significance of FDG PET/CT parameters in patients with non-small cell lung cancer of radiotherapy[J]. Chinese Journal of Radiation Oncology, 2016, 25(2): 121-125.
[1]Opoka L,Kunikowska J,Podgajny Z,et al. Staging of non-small cell lung cancer using CT and integrated PET-CT[J].Pneumonol Alergol Pol,2013,81(1):5-15. [2]Krengli M,Milia ME,Turri L,et al. FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma[J].Radiat Oncol,2010,5:10.DOI:10.1186/1748-717X-5-10. [3]Camps C,Del Pozo N,Blasco A,et al. Importance of quality of life in patients with non-small-cell lung cancer[J].Clin Lung Cancer,2009,10(2):83-90.DOI:10.3816/CLC.2009.n.010. [4]Brundage MD,Davies D,Mackillop WJ.Prognostic factors in non-small cell lung cancer:a decade of progress[J].Chest,2002,122(3):1037-1057.DOI:10.1378/chest.122.3.1037. [5]Lin J,Beer DG.Molecular predictors of prognosis in lung cancer[J].Ann Surg Oncol,2012,19(2):669-676.DOI:10.1245/s10434-011-1967-x. [6]彭红,马美丽,韩宝惠.1,742例Ⅳ期非小细胞肺癌的预后分析[J].中国肺癌杂志,2011,14(4):362-366.DOI:10.3779/j.issn.1009-3419.2011.04.11. Peng H,Ma ML,Han BH.Survival analysis of 1,742 patients with stage ⅠV non-small cell lung cancer[J].Chin J Lung Cancer,2011,14(4):362-366.DOI:10.3779/j.issn.1009-3419.2011.04.11. [7]Imamura Y,Azuma K,Kurata S,et al. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy[J].Lung Cancer,2011,71(1):49-54.DOI:10.1016/j.lungcan.2010.04.004. [8]Nair VJ,MacRae R,Sirisegaram A,et al. Pretreatment[18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy:rethinking the role of positron emission tomography in personalizing treatment based on risk status[J].Int J Radiat Oncol Biol Phys,2014,88(2):312-318.DOI:10.1016/j.ijrobp.2013.10.029. [9]Ulger S,Demirci NY,Eroglu FN,et al. High FDG uptake predicts poorer survival in locally advanced non-small cell lung cancer patients undergoing curative radiotherapy,independently of tumor size[J].J Cancer Res Clin Oncol,2014,140(3):495-502.DOI:10.1007/s00432-014-1591-9. [10]Huang W,Fan M,Liu B,et al. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy[J].J Nucl Med,2014,55(10):1584-1590.DOI:10.2967/jnumed.114.142919. [11]Im H J,Pak K,Cheon G J,et al. Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer:a meta-analysis[J].Eur J Nucl Med Mol Imaging,2015,42(2):241-251.DOI:10.1007/s00259-014-2903-7. [12]Chen HHW,Chiu NT,Su WC,et al. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer[J].Radiology,2012,264(2):559-566.DOI:10.1148/radiol.12111148. [13]Satoh Y,Onishi H,Nambu A,et al. Volume-based parameters measured by using FDG PET/CT in patients with stage Ⅰ NSCLC treated with stereotactic body radiation therapy:prognostic value[J].Radiology,2014,270(1):275-281.DOI:10.1148/radiol.13130652. [14]宋颖秋,王天禄,党军,等.PET-CT下三维适形放疗Ⅲ期非小细胞肺癌的预后分析[J].中华放射肿瘤学杂志,2011,20(5):390-393.DOI:10.3760/cma.j.issn.1004-4221.2011.05.008. Song YQ,Wang TL,Dang J,et al. Outcome and prognostic factors in stage Ⅲ non-small cell lung cancer treated with definitive radiation therapy with PET-CT-based radiotherapy planning[J].Chin J Radiat Oncol,2011,20(5):390-393.DOI:10.3760/cma.j.issn.1004-4221.2011.05.008. [15]裘敬平,李光,党军,等.FDG PET标准摄取值与非小细胞肺癌三维适形放疗预后的相关性[J].中华放射肿瘤学杂志,2010,19(1):28-32.DOI:10.3760/cma.j.issn.1004-4221.2010.01.010. Qiu JP,Li G,Dang J,et al. Prognostic significance of fluorodeoxyglucose standardized uptake value in non-small cell lung cancer treated with 3-dimensional conformal radiation therapy[J].Chin J Radiat Oncol,2010,19(1):28-32.DOI:10.3760/cma.j.issn.1004-4221.2010.01.010. [16]Vu CC,Matthews R,Kim B,et al. Prognostic value of metabolic tumor volume and total lesion glycolysis from 18F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage Ⅰ non-small-cell lung cancer[J].Nucl Med Commun,2013,34(10):959-963.DOI:10.1097/MNM.0b013e32836491a9. [17]宋丽华,宋现让,刘美芹,等.Ⅲ期Ⅳ期非小细胞肺癌预后影响因素分析[J].中华肿瘤杂志,2004,26(6):345-348.DOI:10.3760/j.issn:0253-3766.2004.06.007. Song LH,Song XR,Liu MQ,et al. Prognostic factors in patients with stage Ⅲ and IV non-small cell lung cancer[J].Chin J Oncol,2004,26(6):345-348.DOI:10.3760/j.issn:0253-3766.2004.06.007.
2016, Vol. 25 
